Evidence map›Paper›PMID 25422763›Full record

ArticleJournal of diabetes investigation2014

Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice.

Takahiro Nojiri, Makoto Kurano, Yasunori Tokuhara, Shigeo Ohkubo, Masumi Hara, Hitoshi Ikeda, Kazuhisa Tsukamoto, Yutaka Yatomi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. HDL metabolism and function in diabetes mellitus.Nature reviews. Endocrinology · 2026
    Review
  6. Article
  7. Review
  8. Sphingolipids and Chronic Kidney Disease.Journal of clinical medicine · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Implications of Sphingolipid Metabolites in Kidney Diseases.International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Takahiro NojiriDepartment of Clinical Laboratory, The University of Tokyo Hospital Tokyo, Japan.
Makoto KuranoDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.
Yasunori TokuharaDepartment of Clinical Laboratory, The University of Tokyo Hospital Tokyo, Japan ; The Group of Neurobiology, Division of Health Sciences, Graduate School of Medicine, Osaka University Osaka, Japan.
Shigeo OhkuboDepartment of Clinical Laboratory, The University of Tokyo Hospital Tokyo, Japan.
Masumi HaraDepartment of Medicine IV, Mizonokuchi Hospital, Teikyo University School of Medicine Kawasaki, Japan.
Hitoshi IkedaDepartment of Clinical Laboratory, The University of Tokyo Hospital Tokyo, Japan ; Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.
Kazuhisa TsukamotoDepartment of Metabolism, Diabetes and Nephrology, Aizu Medical Center, Fukushima Medical University Fukushima, Japan.
Yutaka YatomiDepartment of Clinical Laboratory, The University of Tokyo Hospital Tokyo, Japan ; Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.
University of Tokyo Hospital · JPThe University of Tokyo · JPFukushima Medical University · JPTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionSphingosine-1-phosphate (S1P), a multifunctional bioactive lipid mediator, is involved in various diseases. Apolipoprotein M (ApoM) carries S1P on high-density lipoprotein and modulates S1P metabolism to increase the total S1P mass in the body. Both S1P and ApoM are involved in diabetes. MATERIALS AND

methodsThe present study examined the modulation of S1P and ApoM levels in the plasma, liver and kidneys in streptozotocin-induced diabetes (STZ) mice, and the effects of insulin on the S1P and ApoM levels in the plasma and liver in STZ mice and normal mice. We also examined the effects of insulin and glucose on the ApoM levels in HepG2 cells.

resultsIn STZ mice, both the plasma S1P and ApoM levels were higher than those in control mice. The hepatic S1P and ApoM contents were also elevated. The hepatic S1P and ApoM contents were reduced by insulin treatment, whereas high-dose insulin decreased the plasma S1P and ApoM levels. In mice without streptozotocin treatment, the administration of insulin decreased the plasma S1P and ApoM levels, and the hepatic content of ApoM, whereas the hepatic level of S1P was not altered. Treatment with insulin and incubation under a low glucose level decreased the ApoM levels in HepG2 cells. Regarding the kidney, the renal levels of S1P and ApoM were increased in STZ mice, and insulin treatment partially restored this increment.

conclusionsIn STZ mice, the levels of S1P and ApoM in the plasma, liver, and kidneys were increased. Insulin treatment somehow reversed this modulation in STZ mice.

Indexed as

Apolipoprotein MSphingosine-1-phosphateStreptozotocin-induced diabetes mice

Identifiers

PMID25422763
PMCPMC4234226
OpenAlexW2015881389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.